#cohort
Latest news and interesting information about cohort.
Cohort shares jump 12% on FY26 beat
Cohort shares jumped 12% after FY26 profit and revenue beat forecasts. Defense tech firm's record order book underpins outlook. Read on Bond.az.
Benitec Biopharma gene therapy stock shows clinical promise
Benitec Biopharma gene therapy stock shows clinical promise. BB-301 achieves 100% response rate in OPMD. Analysis on Bond.az.
KeyBanc Reiterates Overweight on Walmart, $145 Target
KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.
Immuneering stock jumps on pancreatic cancer trial data
Immuneering stock jumps 12.5% after promising pancreatic cancer trial results.
Director Buys $29,316 in Stock
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock. Bond.az analysis shows the stock may be undervalued.
Avacta reports 2025 results, raises £32.5m for oncology trials
Avacta Group reports 2025 preliminary results, raises £32.5 million for oncology trials. Updates on AVA6103 and AVA6000 programs.
Telix completes enrollment in glioblastoma therapy trial
Telix Pharmaceuticals completes patient enrollment for TLX101-Tx glioblastoma therapy trial.
Quantum BioPharma stock surges on MS imaging study progress
Quantum BioPharma stock surges 10% on promising MS imaging study progress with Massachusetts General Hospital.
DT-216P2 Shows Promise in Friedreich Ataxia Trial
Design Therapeutics announces positive Phase 1/2 trial data for DT-216P2 in Friedreich ataxia, showing clinical improvements and good tolerability.
Ackman explains Alphabet exit for Microsoft stake
Bill Ackman says Alphabet sale was portfolio rebalancing, not a bet against the company; proceeds funded Microsoft stake.
Atisama advances RB042 trial, appoints Bernard Coulie as chair
Atisama advances Phase 1 trial of RB042 and appoints Dr. Bernard Coulie as Board Chair. The drug shows safety; higher-dose results due in H2 2026.
Piper Sandler cuts Boot Barn target on guidance
Piper Sandler lowered Boot Barn price target to $226 from $230, maintaining Overweight. Q4 results beat, FY2027 guidance implies EPS growth up to 18%. Stock down 17% YTD.
Tenaya Reports Interim Gene Therapy Trial Results for Heart Condition
Tenaya Therapeutics reported interim results from its RIDGE-1 trial showing TN-401 gene therapy reduced heart rhythm disturbances by up to 67%. Shares up 114%.
...